Clinical trial
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In…
NCT02545868 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02545868 |
|---|---|
| Title | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis |
| Official title | A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Biological, Drug |
| Interventions | 23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine |
| Enrollment | 102 |
| Start date | Oct 27, 2015 |
| Primary completion | Feb 14, 2017 |
| Completion | Sep 21, 2021 |
| First posted | Sep 10, 2015 |
| Last update posted | Mar 26, 2024 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: